Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024 16:30 ET
|
Cellectis Inc.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference...
CARGO Therapeutics to Participate in Upcoming Investor Conferences
May 28, 2024 08:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 17, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Monthly information on share capital and company voting rights
May 16, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
May 14, 2024 10:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13, 2024 16:47 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
May 13, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024 02:00 ET
|
Cellectis Inc.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca